Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01049984 · ClinicalTrials.gov registry record · Phase 4
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
A Phase 4 study of Parkinson's Disease, sponsored by Teva Neuroscience.
- Completed
- Registry status
- Phase 4
- Development phase
- 328
- Enrollment target
- 20
- Study locations
NCT01049984 is a Phase 4 study of Parkinson's Disease that has completed, run by Teva Neuroscience. The registered enrollment target is 328 participants, below the 640-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT01049984, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Teva Neuroscience.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 328 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rasagiline
Study Locations (20)
California
- Teva Investigational Site 15 - Fountain Valley
- Teva Investigational Site 19 - Fresno
- Teva Investigational Site 36 - Fresno
- Teva Investigational Site 04 - La Jolla
- Teva Investigational Site 29 - Reseda
- Teva Investigational Site 69 - San Francisco
- Teva Investigational Site 02 - Sunnyvale
- Teva Investigational Site 43 - Ventura
Florida
- Teva Investigative Site 63 - Atlantis
- Teva Investigational Site 30 - Boca Raton
- Teva Investigational Site 13 - Clearwater
- Teva Investigational Site 70 - Sunrise
- Teva Investigational Site 41 - Tampa
- Teva Investigational Site 61 - Vero Beach
Arizona
- Teva Investigational Site 34 - Phoenix
- Teva Investigational Site 42 - Sun City
Connecticut
- Teva Investigational Site 44 - Fairfield
- Teva Investigational Site 07 - Manchester
Delaware
- Teva Investigational Site 25 - Newark
Georgia
- Teva Investigational Site 01 - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01049984
The ClinicalTrials.gov registry entry for NCT01049984 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 640-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (49% lower). The listed sponsor is Teva Neuroscience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01049984 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01049984 about?
NCT01049984 is a clinical study titled "Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease". To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
What is the current status of trial NCT01049984?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 328 participants. The study started on 2009-12. Estimated completion is 2012-10.
What conditions does trial NCT01049984 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01049984?
The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).
Who is sponsoring clinical trial NCT01049984?
This trial is sponsored by Teva Neuroscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01049984 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.